Fig. 3.

Fig. 3. Casirivimab displayed severely impaired neutralizing activity against the spike protein when K417N mutation is introduced. Casirivimab or Imdevimab was, either alone (A and B) or in combination (C), mixed with pseudoviruses bearing various mutations and incubated at 37°C for 1 h before wash. Cells were incubated for 72 h prior to being subjected to luciferase activity. Neutralization percentage, compared to antibody-untreated pseudovirus alone, was calculated and plotted (left panels) and antibody’s neutralization IC50 was calculated as described in the Materials and Methods and IC50’s from two independent experiments were averaged and plotted (right panels). *, p < 0.05; ***, p < 0.001.

© J. Microbiol. Biotechnol.